Welcome to our dedicated page for Protara Therapeutics SEC filings (Ticker: TARA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Protara Therapeutics, Inc. (TARA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Protara is a clinical-stage biotechnology company listed on The Nasdaq Global Market under the symbol TARA, and its filings offer insight into the development of its investigational therapies TARA-002 and IV Choline Chloride, as well as its capital raising activities.
Among the key documents available are Form 8-K current reports, where Protara reports material events such as public offerings of common stock under its shelf registration statement on Form S-3, interim clinical data from the Phase 2 ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC), and interim results from the Phase 2 STARBORN-1 trial in pediatric lymphatic malformations (LMs). These filings also describe regulatory feedback from the U.S. Food and Drug Administration (FDA) on registrational trial designs and summarize safety and efficacy data disclosed in associated press releases and investor presentations.
Investors can also use this page to track financing-related disclosures, including details of underwritten public offerings, the number of shares issued, gross proceeds, and the intended use of net proceeds, which Protara states include funding the clinical development of TARA-002 and other clinical programs, as well as working capital and general corporate purposes.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand the implications of clinical updates, regulatory interactions, and financing transactions. Real-time updates from EDGAR mean that new Protara filings, such as additional 8-Ks, quarterly or annual reports when filed, and other registration statements, can be reviewed soon after submission.
For users interested in governance and ownership details, this page also serves as a starting point to locate information typically found in periodic and transactional filings, while AI-generated overviews can make complex regulatory language more accessible to a broader audience.
Protara Therapeutics, Inc. is asking stockholders to vote on seven proposals at its virtual 2026 annual meeting on June 12, 2026. Items include electing three Class III directors, ratifying Ernst & Young LLP as auditor, and advisory votes on executive pay and its frequency.
Stockholders will also consider an amendment to the 2024 Equity Incentive Plan and two charter amendments: one to increase authorized common shares from 100,000,000 to 200,000,000, and another to add officer exculpation as permitted by Delaware law. A record 55,060,500 common shares are entitled to vote as of April 15, 2026.
Protara Therapeutics reports that BlackRock, Inc. beneficially owns 3,387,459 shares of Common Stock, representing 6.3% of the class as of 03/31/2026. The filing states BlackRock has sole voting power for 3,347,945 shares and sole dispositive power for 3,387,459 shares. The schedule notes various persons may have rights to dividends or sale proceeds and is signed by a BlackRock Managing Director on 04/27/2026.
Affiliate reported proposed sales of Common Stock under Rule 144. The filing lists multiple entries by Baker Brothers Life Sciences, L.P. showing reported sale activity on 02/24/2026, 02/25/2026, 03/04/2026, and 03/06/2026 with associated numeric entries in the filing. The record also lists Jefferies LLC as an underwriter reference and an earlier underwriting date of 09/22/2020.
TARA filed a Form 144 notice reporting proposed sales of Common Stock by an affiliate/insider. The filing lists multiple proposed dispositions in late February and early March 2026, including specific lots: 26,755 shares on 02/24/2026, 78,716 shares on 02/25/2026, 35,173 shares on 03/04/2026, and 38,277 shares on 03/06/2026. The filing names Jefferies LLC as underwriter in connection with the securities to be sold.
Protara Therapeutics, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held virtually on June 12, 2026 at 12:00 p.m. Eastern Time. The Record Date is April 15, 2026 and 55,060,500 shares of common stock were outstanding on that date.
Stockholders will vote on seven proposals including election of three Class III directors, ratification of Ernst & Young LLP as auditor, advisory votes on executive compensation and frequency, amendment of the 2024 Equity Incentive Plan, an amendment to increase authorized common shares from 100,000,000 to 200,000,000, and an amendment to allow officer exculpation under Delaware law. The proxy statement explains voting procedures, broker non-votes, quorum rules and how to access proxy materials online.
Protara Therapeutics, Inc. Chief R&D Officer Jacqueline Zummo sold 1,134 shares of Common Stock on April 8, 2026 at $5.40 per share in an open-market transaction. The sale occurred automatically under a Rule 10b5-1 trading plan established on December 31, 2025. Following the sale, she directly holds 94,827 shares.
Protara Therapeutics Chief R&D Officer sells shares under trading plan. Jacqueline Zummo completed an open-market sale of 22,598 shares of Protara Therapeutics common stock at a weighted average price of $5.26 per share. After this automatic sale under a Rule 10b5-1 trading plan established on December 31, 2025, she directly holds 95,961 shares.
Protara Therapeutics, Inc. reported updated interim data from its ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with carcinoma in situ non-muscle invasive bladder cancer that is Bacillus Calmette-Guérin (BCG)-Unresponsive. The company confirmed the six-month complete response rate for the 25th BCG-Unresponsive patient, yielding an average six-month complete response rate of 68.0% in these 25 patients. This result is consistent with the previously announced six-month complete response rate of 68.2% and remains meaningfully above 41.9%. Based on this outcome, Protara determined that a condition in its April 2024 common stock purchase warrants has been satisfied, so those warrants are exercisable at $5.25 per share at any time on or prior to June 29, 2026.